There is a FANTASTIC, DETAILED and HOPE-filled interview podcast on MSS-CRC from ASCO-2016 including an interview with Dr. Johanna Bendell (a Principal Investigator of the MEK-PDL1 trial) who explains the HUGE MEK+PDL1 breakthrough in easy to understand terms including optimism (but still unproven) it will have activity in a significant percentage of patients with both KRAS-mutant and KRAS-wildtype MSS-CRC (i.e. the entire patient population). Dr. Bendell is a clinical trial expert.
The concept of immunoscore (very important for MSS-CRC immunotherapy to guide patients towards an appropriate clinical trial) is also discussed by Dr. Jérôme Galon. Next, a representative from Genentech explains the clinical trial design process in the age of immunotherapy.
Sit down, take 30 minutes to listen, it is worth it! AND SHARE IT – patient education is so important in today’s fast moving research world
I have organized my various MEK-PDL1 trial coverage into a single new post - which includes a link to this VERY good interview.
https://adventuresinlivingterminallyopt ... estigator/